Reconsidering time from diagnosis to treatment in acute myeloid leukemia: from therapeutic urgency to biologically informed timing

TDT should be considered a biology-adapted decision rather than a measure of urgency: brief, purposeful delays to refine genomic profiling may optimize treatment selection without compromising outcomes, whereas system-driven delays remain harmful and inequitable.